Journal of Digestive Cancer Research

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지
DOI QR코드

DOI QR Code

Gastric Cancer and Non-Helicobacter pylori Microbiota

위암과 미생물총

  • Yu Jin Kim (Department of Gastroenterology, Kangnam Sacred Heart Hospital, Hallym University College of Medicine)
  • 김유진 (한림대학교 의과대학 강남성심병원 소화기내과)
  • Received : 2024.04.08
  • Accepted : 2024.04.15
  • Published : 2024.04.20
Download PDF
⟨ Previous Next ⟩

Abstract

Gastric cancer is the 4th leading cause of death worldwide. The primary cause of gastric cancer is known to be Helicobacter pylori (H. pylori). The advancement of molecular biology has enabled the identification of microbiomes that could not be confirmed through cultivation, and it has been revealed that the microbial communities vary among normal mucosa, atrophic gastritis, intestinal metaplasia, and gastric cancer. It has also been confirmed that the composition of the microbial community differs depending on the presence or absence of H. pylori. Whether changes in the microbiome are causative factors in the carcinogenesis process is not yet clear. Experiments using animal models and in vitro studies on the role of microbes other than H. pylori in the carcinogenic process are underway, but the data is still insufficient.

Keywords

References

  1. Anderson WF, Camargo MC, Fraumeni JF Jr, Correa P, Rosenberg PS, Rabkin CS. Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA 2010;303:1723-1728. https://doi.org/10.1001/jama.2010.496
  2. Zhou F, Shi J, Fang C, Zou X, Huang Q. Gastric carcinomas in young (younger than 40 years) Chinese patients: clinicopathology, family history, and postresection survival. Medicine (Baltimore) 2016;95:e2873. https://doi.org/10.1097/MD.0000000000002873
  3. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-194. https://doi.org/10.1001/jama.291.2.187
  4. Bik EM, Eckburg PB, Gill SR, et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci U S A 2006;103:732-737. https://doi.org/10.1073/pnas.0506655103
  5. Forman D, Newell DG, Fullerton F, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ 1991;302:1302-1305. https://doi.org/10.1136/bmj.302.6788.1302
  6. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991;325:1132-1136. https://doi.org/10.1056/NEJM199110173251604
  7. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127-1131. https://doi.org/10.1056/NEJM199110173251603
  8. Huang JQ, Hunt RH. The evolving epidemiology of Helicobacter pylori infection and gastric cancer. Can J Gastroenterol 2003;17 Suppl B:18B-20B. https://doi.org/10.1155/2003/692808
  9. Kawai S, Wang C, Lin Y, Sasakabe T, Okuda M, Kikuchi S. Lifetime incidence risk for gastric cancer in the Helicobacter pylori-infected and uninfected population in Japan: a Monte Carlo simulation study. Int J Cancer 2022; 150:18-27. https://doi.org/10.1002/ijc.33773
  10. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994;61:1-241.
  11. Poh AR, O'Donoghue RJ, Ernst M, Putoczki TL. Mouse models for gastric cancer: matching models to biological questions. J Gastroenterol Hepatol 2016;31:1257-1272. https://doi.org/10.1111/jgh.13297
  12. Yakirevich E, Resnick MB. Pathology of gastric cancer and its precursor lesions. Gastroenterol Clin North Am 2013;42:261-284. https://doi.org/10.1016/j.gtc.2013.01.004
  13. Hsieh YY, Tung SY, Pan HY, et al. Increased abundance of Clostridium and Fusobacterium in gastric microbiota of patients with gastric cancer in Taiwan. Sci Rep 2018;8:158. https://doi.org/10.1038/s41598-017-18596-0
  14. Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer 2015;136:487-490. https://doi.org/10.1002/ijc.28999
  15. Nguyen TH, Mallepally N, Hammad T, et al. Prevalence of Helicobacter pylori positive non-cardia gastric adenocarcinoma is low and decreasing in a US population. Dig Dis Sci 2020;65:2403-2411. https://doi.org/10.1007/s10620-019-05955-2
  16. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. IARC monographs on the evaluation of carcinogenic risks to humans. Ingested nitrate and nitrite, and cyanobacterial peptide toxins. IARC Monogr Eval Carcinog Risks Hum 2010;94:v-vii, 1-412.
  17. von den Velden R. Ueber vorkommen und mandgel der freien salzsaure in magensaft bei gastrektasie. Dtsch Arch Klin Med 1879;23:369-399.
  18. Oppler B. Zur Kenntniss des Mageninhalts beim Carcinoma ventriculi. Dtsch Med Wochenschr 1895;21:73-75. German. https://doi.org/10.1055/s-0029-1199648
  19. Heinemann PG, Ecker EE. A study of the Boas-Oppler bacillus. J Bacteriol 1916;1:435-444. https://doi.org/10.1128/jb.1.4.435-444.1916
  20. Giannella RA, Broitman SA, Zamcheck N. Gastric acid barrier to ingested microorganisms in man: studies in vivo and in vitro . Gut 1972;13:251-256. https://doi.org/10.1136/gut.13.4.251
  21. Relevance of N-nitroso compounds to human cancer: exposures and mechanisms. Proceedings of the IXth International Symposium on N-Nitroso Compounds. Baden, Austria, 1-5 September 1986. IARC Sci Publ 1987;(84):1-663.
  22. Jakszyn P, Bingham S, Pera G, et al. Endogenous versus exogenous exposure to N-nitroso compounds and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study. Carcinogenesis 2006;27:1497-1501. https://doi.org/10.1093/carcin/bgl019
  23. Xu L, Qu YH, Chu XD, et al. Urinary levels of Nnitroso compounds in relation to risk of gastric cancer: findings from the Shanghai cohort study. PLoS One 2015;10:e0117326. https://doi.org/10.1371/journal.pone.0117326
  24. Sjostedt S, Kager L, Heimdahl A, Nord CE. Microbial colonization of tumors in relation to the upper gastrointestinal tract in patients with gastric carcinoma. Ann Surg 1988;207:341-346. https://doi.org/10.1097/00000658-198803000-00020
  25. Sjostedt S, Heimdahl A, Kager L, Nord CE. Microbial colonization of the oropharynx, esophagus and stomach in patients with gastric diseases. Eur J Clin Microbiol 1985;4:49-51. https://doi.org/10.1007/BF02148660
  26. Tsuda A, Suda W, Morita H, et al. Influence of protonpump inhibitors on the luminal microbiota in the gastrointestinal tract. Clin Transl Gastroenterol 2015;6:e89. https://doi.org/10.1038/ctg.2015.20
  27. Minalyan A, Gabrielyan L, Scott D, Jacobs J, Pisegna JR. The gastric and intestinal microbiome: role of proton pump inhibitors. Curr Gastroenterol Rep 2017;19:42. https://doi.org/10.1007/s11894-017-0577-6
  28. Li TH, Qin Y, Sham PC, Lau KS, Chu KM, Leung WK. Alterations in gastric microbiota after H. pylori eradication and in different histological stages of gastric carcinogenesis. Sci Rep 2017;7:44935. https://doi.org/10.1038/srep44935
  29. Massarrat S, Saniee P, Siavoshi F, Mokhtari R, Mansour-Ghanaei F, Khalili-Samani S. The effect of Helicobacter pylori infection, aging, and consumption of proton pump inhibitor on fungal colonization in the stomach of dyspeptic patients. Front Microbiol 2016;7:801. https://doi.org/10.3389/fmicb.2016.00801
  30. Azab M, Doo L, Doo DH, et al. Comparison of the hospital-acquired Clostridium difficile infection risk of using proton pump inhibitors versus histamine-2 receptor antagonists for prophylaxis and treatment of stress ulcers: a systematic review and meta-analysis. Gut Liver 2017;11:781-788. https://doi.org/10.5009/gnl16568
  31. Rosen R, Hu L, Amirault J, Khatwa U, Ward DV, Onderdonk A. 16S community profiling identifies proton pump inhibitor related differences in gastric, lung, and oropharyngeal microflora. J Pediatr 2015;166:917-923. https://doi.org/10.1016/j.jpeds.2014.12.067
  32. Wang K, Lin HJ, Perng CL, et al. The effect of H2- receptor antagonist and proton pump inhibitor on microbial proliferation in the stomach. Hepatogastroenterology 2004;51:1540-1543.
  33. Peterson WL, Mackowiak PA, Barnett CC, Marling-Cason M, Haley ML. The human gastric bactericidal barrier: mechanisms of action, relative antibacterial activity, and dietary influences. J Infect Dis 1989;159:979-983. https://doi.org/10.1093/infdis/159.5.979
  34. Choi HI, Choi JP, Seo J, et al. Helicobacter pylori-derived extracellular vesicles increased in the gastric juices of gastric adenocarcinoma patients and induced inflammation mainly via specific targeting of gastric epithelial cells. Exp Mol Med 2017;49:e330. https://doi.org/10.1038/emm.2017.47
  35. Monstein HJ, Tiveljung A, Kraft CH, Borch K, Jonasson J. Profiling of bacterial flora in gastric biopsies from patients with Helicobacter pylori -associated gastritis and histologically normal control individuals by temperature gradient gel electrophoresis and 16S rDNA sequence analysis. J Med Microbiol 2000;49:817-822. https://doi.org/10.1099/0022-1317-49-9-817
  36. DeLong EF. Microbial metagenomics, metatranscriptomics, and metaproteomics. Amsterdam: Academic Press, 2013.
  37. Zhu Z, Ren J, Michail S, Sun F. MicroPro: using metagenomic unmapped reads to provide insights into human microbiota and disease associations. Genome Biol 2019; 20:154. Erratum in: Genome Biol 2019;20:214. https://doi.org/10.1186/s13059-019-1773-5
  38. Andersson AF, Lindberg M, Jakobsson H, Backhed F, Nyren P, Engstrand L. Comparative analysis of human gut microbiota by barcoded pyrosequencing. PLoS One 2008;3:e2836. https://doi.org/10.1371/journal.pone.0002836
  39. Sohn SH, Kim N, Jo HJ, et al. Analysis of gastric body microbiota by pyrosequencing: possible role of bacteria other than Helicobacter pylori in the gastric carcinogenesis. J Cancer Prev 2017;22:115-125. Erratum in: J Cancer Prev 2017;22:267. https://doi.org/10.15430/JCP.2017.22.2.115
  40. Williams C, McColl KE. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006;23:3-10. https://doi.org/10.1111/j.1365-2036.2006.02707.x
  41. Shao D, Vogtmann E, Liu A, et al. Microbial characterization of esophageal squamous cell carcinoma and gastric cardia adenocarcinoma from a high-risk region of China. Cancer 2019;125:3993-4002. https://doi.org/10.1002/cncr.32403
  42. Meng C, Bai C, Brown TD, Hood LE, Tian Q. Human gut microbiota and gastrointestinal cancer. Genomics Proteomics Bioinformatics 2018;16:33-49. https://doi.org/10.1016/j.gpb.2017.06.002
  43. Aviles-Jimenez F, Vazquez-Jimenez F, Medrano-Guzman R, Mantilla A, Torres J. Stomach microbiota composition varies between patients with non-atrophic gastritis and patients with intestinal type of gastric cancer. Sci Rep 2014;4:4202. https://doi.org/10.1038/srep04202
  44. Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, et al. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut 2018;67:226-236. https://doi.org/10.1136/gutjnl-2017-314205
  45. Li Q, Yu H. The role of non-H. pylori bacteria in the development of gastric cancer. Am J Cancer Res 2020;10:2271-2281.
  46. Dicksved J, Lindberg M, Rosenquist M, Enroth H, Jansson JK, Engstrand L. Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls. J Med Microbiol 2009;58:509-516. https://doi.org/10.1099/jmm.0.007302-0
  47. Coker OO, Dai Z, Nie Y, et al. Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut 2018;67:1024-1032. https://doi.org/10.1136/gutjnl-2017-314281
  48. Park CH, Lee AR, Lee YR, Eun CS, Lee SK, Han DS. Evaluation of gastric microbiome and metagenomic function in patients with intestinal metaplasia using 16S rRNA gene sequencing. Helicobacter 2019;24:e12547. https://doi.org/10.1111/hel.12547
  49. Wang L, Zhou J, Xin Y, et al. Bacterial overgrowth and diversification of microbiota in gastric cancer. Eur J Gastroenterol Hepatol 2016;28:261-266. https://doi.org/10.1097/MEG.0000000000000542
  50. Hu YL, Pang W, Huang Y, Zhang Y, Zhang CJ. The gastric microbiome is perturbed in advanced gastric adenocarcinoma identified through shotgun metagenomics. Front Cell Infect Microbiol 2018;8:433. https://doi.org/10.3389/fcimb.2018.00433
  51. Eun CS, Kim BK, Han DS, et al. Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods. Helicobacter 2014;19:407-416. https://doi.org/10.1111/hel.12145
  52. Castano-Rodriguez N, Goh KL, Fock KM, Mitchell HM, Kaakoush NO. Dysbiosis of the microbiome in gastric carcinogenesis. Sci Rep 2017;7:15957. https://doi.org/10.1038/s41598-017-16289-2
  53. Liu X, Shao L, Liu X, et al. Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer. EBioMedicine 2019;40:336-348. https://doi.org/10.1016/j.ebiom.2018.12.034
  54. Stewart OA, Wu F, Chen Y. The role of gastric microbiota in gastric cancer. Gut Microbes 2020;11:1220-1230. https://doi.org/10.1080/19490976.2020.1762520
  55. Vuik F, Dicksved J, Lam SY, et al. Composition of the mucosa-associated microbiota along the entire gastrointestinal tract of human individuals. United European Gastroenterol J 2019;7:897-907. https://doi.org/10.1177/2050640619852255
  56. Maldonado-Contreras A, Goldfarb KC, Godoy-Vitorino F, et al. Structure of the human gastric bacterial community in relation to Helicobacter pylori status. ISME J 2011;5:574-579. https://doi.org/10.1038/ismej.2010.149
  57. Lofgren JL, Whary MT, Ge Z, et al. Lack of commensal flora in Helicobacter pylori -infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. Gastroenterology 2011;140:210-220. https://doi.org/10.1053/j.gastro.2010.09.048
  58. Allison CC, Ferrero RL. Role of virulence factors and host cell signaling in the recognition of Helicobacter pylori and the generation of immune responses. Future Microbiol 2010;5:1233-1255. https://doi.org/10.2217/fmb.10.84
  59. Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology 2015;148:719-731.e3. https://doi.org/10.1053/j.gastro.2015.01.040
  60. Miftahussurur M, Yamaoka Y, Graham DY. Helicobacter pylori as an oncogenic pathogen, revisited. Expert Rev Mol Med 2017;19:e4. https://doi.org/10.1017/erm.2017.4
  61. Hanada K, Graham DY. Helicobacter pylori and the molecular pathogenesis of intestinal-type gastric carcinoma. Expert Rev Anticancer Ther 2014;14:947-954. https://doi.org/10.1586/14737140.2014.911092
  62. Kidane D. Molecular mechanisms of H. pylori -induced DNA double-strand breaks. Int J Mol Sci 2018;19:2891. https://doi.org/10.3390/ijms19102891
  63. Gunathilake MN, Lee J, Choi IJ, et al. Association between the relative abundance of gastric microbiota and the risk of gastric cancer: a case-control study. Sci Rep 2019;9:13589. Erratum in: Sci Rep 2021;11:21669. https://doi.org/10.1038/s41598-019-50054-x
  64. Montalban-Arques A, Wurm P, Trajanoski S, et al. Propionibacterium acnes overabundance and natural killer group 2 member D system activation in corpus-dominant lymphocytic gastritis. J Pathol 2016;240:425-436. https://doi.org/10.1002/path.4782
  65. Ling Z, Shao L, Liu X, et al. Regulatory T cells and plasmacytoid dendritic cells within the tumor microenvironment in gastric cancer are correlated with gastric microbiota dysbiosis: a preliminary study. Front Immunol 2019;10:533. https://doi.org/10.3389/fimmu.2019.00533
  66. Huang XM, Liu XS, Lin XK, et al. Role of plasmacytoid dendritic cells and inducible costimulator-positive regulatory T cells in the immunosuppression microenvironment of gastric cancer. Cancer Sci 2014;105:150-158. https://doi.org/10.1111/cas.12327
  67. Ahmetlic F, Riedel T, Homberg N, et al. Regulatory T cells in an endogenous mouse lymphoma recognize specific antigen peptides and contribute to immune escape. Cancer Immunol Res 2019;7:600-608. https://doi.org/10.1158/2326-6066.CIR-18-0419